News & Press

More than 100 million individuals worldwide suffer from organ fibrosis, a pathological proliferation of connective tissue in an organ, such as the lung, heart and liver. Hardly any causal treatments are available to date. The unmet medical need is partly due to the fact that the existing disease models for fibrosis research are insufficient and little predictive. Coordinated by the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, four Fraunhofer institutes (ITEM, IWS, MEVIS und IMW) have joined forces in the FibroPaths® project aimed at enabling rapid and safe development of antifibrotic drugs.

The new institute building of Fraunhofer MEVIS opens its doors and presents itself to the public on the Day of Architecture on Sunday, June 26.

Fraunhofer MEVIS participates at the 5th edition of the SILBERSALZ Science & Media Forum taking place on 17-18 June 2022 at the Leopoldina – National Academy of Sciences, in Halle (Saale), Germany.

Fraunhofer MEVIS is well represented at the 105th Annual Meeting of the German Society of Pathology (DGP 2022) from June 9 to 11 in Muenster. The conference offers researchers the opportunity to exchange ideas directly and intensively after the last purely digital meetings. The motto of the conference is: Connective (tissue) pathology – what connects us!